Drug Profile
Research programme: atherosclerosis therapies - Merck & Co
Alternative Names: Atherosclerosis therapies research programme - Merck & CoLatest Information Update: 31 Mar 2010
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 05 Mar 2008 This programme is still in active development
- 17 May 2005 Preclinical trials in Atherosclerosis in USA (unspecified route)